Practice Contact Information
6420 Rockledge Drive
Web Site: https://www.hopkinsmedicine.org/profiles/results/directory/profile/10001011/nicole-schmitt
Areas of Interest in Head and Neck Surgery
Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon
Nicole C. Schmitt, M.D., is a head and neck cancer surgeon in the Washington, D.C. area, as well as an assistant professor of otolaryngology-head and neck surgery for Johns Hopkins University School of Medicine. Dr. Schmitt has been integral in building Johns Hopkins’ head and neck oncology multidisciplinary program in the National Capital Region. She is board certified in head and neck surgery by the American Board of Otolaryngology.
Dr. Schmitt has an expertise in surgical treatment and surveillance of patients with benign and malignant tumors of the head and neck; robotic surgery; benign and malignant thyroid and parathyroid disease; melanoma and non-melanoma skin cancers of the head and neck; squamous cell carcinoma of the upper aerodigestive tract; salivary tumors; and surgery for obstructive sleep apnea.
Dr. Schmitt earned her medical degree from the Washington University School of Medicine in St. Louis, Missouri. She completed a residency in otolaryngology at the University of Washington in Seattle, Washington, where she also completed a research fellowship that studied toxicities of cisplatin chemotherapy in the mouse inner ear and kidney. Dr. Schmitt continued her studies with a fellowship in head and neck surgical oncology and tumor biology at the University of Pittsburgh, where she went on to serve as a clinical instructor for their Department of Otolaryngology-Head and Neck Surgery.
Dr. Schmitt is a principal investigator in the Otolaryngology Surgeon Scientist Program at the National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health. Her research interests include the use of platinum-based chemotherapy drugs and immunotherapy for the treatment of head and neck cancer. She has contributed to numerous publications, presentations, posters and book chapters. Dr. Schmitt has received research funding from the Johns Hopkins University Department of Otolaryngology, the NIDCD/NIH, the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. She is an ad hoc reviewer for Otolaryngology-Head and Neck Surgery, Head and Neck, JAMA Otolaryngology-Head and Neck Surgery, and Oral Oncology, where she also serves as an editorial board member. Dr. Schmitt is also a clinical mentor of otolaryngology for residents from Walter Reed National Military Medical Center.
NCT03225157: Hearing Loss and the Effects of Statin Drugs in People with Head and Neck Squamous Cell Carcinoma Treated with Cisplatin Chemoradiation
- Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ, Spielbauer K, Van Waes C, Schmitt NC. Cisplatin alters anti-tumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res 2017;5:1141-1151.
- Schmitt NC, Page BR. Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients. Int J Audiol, 2017;Jul 20:1-6. doi: 10.1080/14992027.2017.1353710.
- Schmitt NC, Rubel EW, Nathanson NM. Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J Neurosci 2009; 29:3843-3851.
- Mitchell RM, Mendez E, Schmitt NC, Bhrany AD, Futran ND. Antibiotic prophylaxis in patients receiving free flap reconstruction. JAMA Otolaryngol 2015;141: 1096-103. Role: Data collection and analysis, writing and revision of manuscript.
- Schmitt NC, Trivedi S, Ferris RL. STAT1 activation is enhanced by cisplatin and variably affected by EGFR inhibition in HNSCC Mol Cancer Ther. 2015;14: 2103-11.
- Schmitt NC, Sharma A, Gilbert MR, Kim S. Early T stage salivary duct carcinoma: Outcomes and implications for patient counseling. Otolaryngol Head Neck Surg 2015;153: 795-8.
- Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U, Kim SW. Salivary Duct Carcinoma: A Single-Institution, 20-Year Review of 75 Cases. JAMA Otolaryngol 2016;142:489-95.Role: Data collection and analysis, writing and revision of manuscript.
- Lang Kuhs KA, Kreimer AR, Trivedi S, Holzinger D, Pawlita M, Pfeiffer RM, Gibson SP, Schmitt NC, Hildesheim A, Waterboer T, Ferris RL. HPV16 antibodies are highly sensitive for HPV-drive oropharyngeal cancer and are associated with risk of recurrence. Cancer 2017;doi: 10.1002/cncr.30966.
- Lang Kuhs KA, Pawlita M, Trivedi S, Gibson SP, Schmitt NC, Argiris A, Kreimer AR, Ferris RL, Waterboer T. Characterization of human papillomavirus antibodies in individuals with head and neck Cancer Epidemiol 2016;42:46-52.
- Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer. Ann Oncol 2016; 27:2257-62.
- Kansy BA, Concha-Benavente F, Srivastava R, Jie HB, Shayan G, Yu L, Moskowitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL. Exhausted PD-1-high CD8+ T cells are associated with HPV and survival in head and neck cancer while PD-1-low cells are activated and reversible with anti-PD-1 therapy. Cancer Research 2017; doi: 10.1158/0008-5472.CAN-16-3167.